VANDA PHARMACEUTICALS INC. Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) had Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) of $20.00 thousand as of 2012-06-30, per its 10-Q filed 2012-08-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLosses1 · last filed 2012-08-03
- 2012-06-30: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $20.00K.
- 2011-12-31: Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) $9.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Losses (Deprecated 2013-01-31) |
|---|---|
| 2012-06-30 | $20.00K 10-Q · filed 2012-08-03 |
| 2011-12-31 | $9.00K 10-Q · filed 2012-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |